Silo Pharma Regains Nasdaq Compliance After Stock Closes Above $1
SILO•On June 17, 2026, Silo Pharma regained compliance with Nasdaq Listing Rule 5550(a)(2) after its common stock closed above the $1 minimum bid requirement. The company is advancing toward a first-in-human trial of its PTSD candidate SPC-15 and developing its QwikAgents AI drug delivery platform.
1. Regains Nasdaq Compliance
As of June 17, 2026, Silo Pharma received confirmation that its common stock met the minimum $1 closing bid price required by Nasdaq Listing Rule 5550(a)(2), closing the compliance matter and avoiding potential delisting. Trading on the Nasdaq Capital Market continues unchanged.
2. Pipeline Progress and Outlook
The company highlights its lead therapeutic SPC-15 targeting post-traumatic stress disorder as it approaches a first-in-human clinical trial, while its QwikAgents platform leverages AI for novel drug delivery systems. Silo Pharma remains focused on developing treatments for PTSD, chronic pain and CNS diseases through collaborations with leading research institutions.
